



AHCL/ SE/13/2025-26

August 12, 2025

The National Stock Exchange of India Limited "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031	BSE Limited Department of Corporate Services 1 st Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031
Symbol: AMRUTANJAN	Scrip Code: 590006

Dear Sir / Madam,

Sub: Outcome of the Board Meeting

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **August 12, 2025** had inter-alia:

- (i) Approved the Unaudited Financial Results for the quarter ended June 30, 2025, as recommended by the Audit Committee at its meeting held on August 12, 2025. The same along with the Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Appointment of M/s. SPNP & Associates, Practicing Company Secretaries, as Secretarial Auditor for a term of five consecutive financial years commencing from April 1, 2025 till March 31, 2030 subject to approval of the members in the ensuing Annual General Meeting.
- (iii) Holding the Eighty Eighth (88th) Annual General Meeting (AGM) of the Company on **September 23, 2025 (Tuesday)** through Video Conference ("VC")/ Other Audio Visual Means ("OAVM")
- (iv) The record date for determining the eligibility of shareholders to vote on the resolutions proposed at the 88th AGM of the Company and for the payment of the Final Dividend has been fixed as **Tuesday, September 16, 2025**.
- (v) The Share transfer register shall be closed from **Wednesday, September 17, 2025 to Tuesday, September 23, 2025 (both days inclusive)**.

The Board Meeting commenced at 12:00 P.M and concluded at 3.45 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

(Gagan Preet Singh)
General Manager- Legal
Company Secretary-cum-Compliance Officer

Encl:

1. Un-audited Standalone Financials Results for the quarter ended June 30, 2025
2. Limited Review Report

AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Statement of Unaudited Financial Results for the quarter ended 30 June 2025

	Particulars	(Amount in INR Lakhs)			
		Quarter ended		Year ended	
		30 June 2025 (Unaudited)	31 March 2025 (Audited - refer note 5)	30 June 2024 (Unaudited)	31 March 2025 (Audited)
I	Revenue from operations	9,404.57	13,541.36	8,373.60	45,181.63
II	Other income	442.74	481.93	445.20	1,767.87
III	Total income (I + II)	9,847.31	14,023.29	8,818.80	46,949.50
IV	Expenses				
	(a) Cost of materials consumed	2,123.63	3,494.97	2,150.98	10,059.69
	(b) Purchase of stock-in-trade	3,116.27	3,093.08	2,730.86	12,317.94
	(c) Changes in inventories of finished goods, work-in progress and stock-in-trade	(300.88)	311.33	(481.11)	(56.90)
	(d) Employee benefits expense	1,601.31	1,601.73	1,385.94	5,910.27
	(e) Finance cost	5.15	4.33	6.46	21.92
	(f) Depreciation and amortisation expense	153.07	162.22	158.73	652.61
	(g) Other expenses				
	- Advertisement and selling expenditure	736.94	1,587.73	876.78	5,611.04
	- Others	1,282.55	1,682.33	1,355.28	5,519.53
	Total expenses (IV)	8,718.04	11,937.72	8,183.92	40,036.10
V	Profit before tax (III - IV)	1,129.27	2,085.57	634.88	6,913.40
VI	Tax expenses	298.15	567.79	173.32	1,829.93
VII	Profit after tax (V - VI)	831.12	1,517.78	461.56	5,083.47
VIII	Other comprehensive income / (loss)				
	Items that will not be reclassified subsequently to profit or loss				
	Re-measurement gain/(loss) on defined benefit plans	(7.52)	(5.46)	(3.94)	(105.87)
	Income tax relating to items that will not be reclassified to profit or loss	1.89	1.38	0.99	26.65
	Other comprehensive income/ (loss), net of taxes	(5.63)	(4.08)	(2.95)	(79.22)
IX	Total comprehensive income (VII + VIII)	825.49	1,513.70	458.61	5,004.25
	Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11
	Other equity				32,372.35
	Earnings per equity share				
	Basic earnings per share (INR)	2.87	5.25	1.60	17.58
	Diluted earnings per share (INR)	2.87	5.25	1.60	17.58
		(not annualised)	(not annualised)	(not annualised)	(annualised)
	<i>See accompanying notes to Unaudited financial results</i>				

[Signature]




AMRUTANJAN HEALTH CARE LIMITED
CIN No : L24231TN1936PLC000017
Registered Office: No. 103 (Old No. 42-45), Luz Church Road
Mylapore, Chennai - 600 004

Notes:

1. The above unaudited financial results for the quarter ended 30 June 2025 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12 August 2025. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
2. These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
3. The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.
4. During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024.
5. The figures for the quarter ended 31 March 2025 are the balancing figures between audited figures in respect of the full financial year and published unaudited year to date figures upto the end of the third quarter of the relevant financial year, which were subjected to limited review and not subjected to audit.
6. The unaudited financial results of the Company for the Quarter ended 30 June 2025 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website www.amrutanjan.com.
7. **Segment reporting in the Unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segments (represents Pain Management Centre).

Particulars		(Amount in INR Lakhs)			
		30 June 2025 (Unaudited)	Quarter ended 31 March 2025 (Audited - refer note 5)	30 June 2024 (Unaudited)	Year ended 31 March 2025 (Audited)
1 Segment revenue					
a OTC Products		5,697.24	8,278.34	4,605.49	29,002.99
b Women's Hygiene		2,860.75	3,445.55	2,658.01	12,396.25
c Beverages		776.01	1,766.97	1,095.51	3,643.01
d Others		70.57	50.50	14.59	139.38
Total		9,404.57	13,541.36	8,373.60	45,181.63
2 Segment results					
a OTC Products		1,079.14	2,026.01	563.00	6,557.17
b Women's Hygiene		14.85	(177.23)	(21.22)	(391.05)
c Beverages		(299.82)	34.40	(125.06)	(243.56)
d Others		(4.51)	(22.72)	(29.05)	(81.43)
Total		789.66	1,860.46	387.67	5,841.13
Less: Finance cost		5.15	4.33	6.46	21.92
Add: Interest income net of other unallocable expenditure		344.76	229.44	253.67	1,094.19
Total profit before tax		1,129.27	2,085.57	634.88	6,913.40
3 Segment assets					
a OTC Products		6,769.06	6,800.73	6,636.72	6,800.73
b Women's Hygiene		5,707.88	5,209.00	2,177.06	5,209.00
c Beverages		2,736.46	3,503.26	2,932.12	3,503.26
d Others		125.54	122.13	119.03	122.13
e Unallocated assets		26,562.01	26,503.68	24,905.86	26,503.68
Total		41,900.95	42,138.80	36,770.79	42,138.80
4 Segment liabilities					
a OTC Products		5,084.47	5,539.80	4,668.49	5,539.80
b Women's Hygiene		1,289.62	1,646.36	1,072.81	1,646.36
c Beverages		1,217.50	1,359.50	954.58	1,359.50
d Others		52.18	42.67	18.73	42.67
e Unallocated liabilities		726.28	889.01	748.74	889.01
Total		8,370.05	9,477.34	7,463.35	9,477.34
Total capital employed in the Company		33,530.90	32,661.46	29,307.44	32,661.46

For Amrutanjan Health Care Limited



S Sambhu Prasad
Chairman & Managing Director
DIN: 00015729

Date: 12 August 2025
Place: Chennai

Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 30 June 2025 ("the Statement") in which are included the unaudited financial results of Amrutanjan Health Care Limited ESOP trust ("ESOP Trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022


R Kalyana Sundara Rajan

Partner

Membership No.: 221822

UDIN: 25221822BMMKDU9701

Chennai

12 August 2025

Registered Office: